Pulmonx Corporation (LUNG)

From the record

Pulmonx Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Pulmonx Corporation's 8 filed years say what it did: revenue went from $20 million in fiscal 2018 to $90 million in fiscal 2025, up 24.1% a year; it rose in 7 of 7 years; it never fell from a peak; net income was positive in 0 of 8 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pulmonx Corporation lost about 100 cents for every dollar of shareholders' money, and gross profitability: its products earned about 52 cents per dollar of everything the company owns. Leverage: it owed about 58 cents per dollar of assets, and net share issuance: its share count grew 4.0% over the year (the filed statements).

From the record

Pulmonx Corporation's standing among 109 graded names in its industry family: revenue of $90 million in fiscal 2025 ranks in the top 48% by size; a net margin of -59.7% ranks in the bottom 32%; revenue growth of 19% a year over the last 3 filed years ranks in the top 39% (its annual reports).

From the record

Pulmonx Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is French, Glendon E. III (President and CEO, as filed), filing under that title since 2025-12-03, 11 months (bottom 20% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 39%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 15%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Pulmonx Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $70 million against debt of $37 million leaves 25.5% of its assets as net cash, top 32% of its family; cash from operations less capital spending is -36.3% of revenue (bottom 34%); a gross margin of 74.2% (top 25%); research spending of 21.5% of revenue (top 37%) (its annual report).

From the record

Pulmonx Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 19% a year over the last three filed years against 24.1% over all 8, slowing (bottom 36% of its family); the newest year grew 8% (bottom 35%); research spending grew 8.2% a year (top 45%); capital spending grew -30% a year (bottom 19%) (its annual reports). Pulmonx Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Pulmonx Corporation's newest year against its own record: revenue of $90 million in fiscal 2025 came in 13.6% below the $105 million its prior three years' pace pointed to (bottom 28% of its family); net income of $54 million against a prior three-year average of $59 million (bottom 43%); a net margin of -59.7% against -88.6% before (top 28%) (its annual reports).